Biopharma teams don’t lose because they lack ambition. They lose because they’re late.
Late to the market. Late to the payer conversation. Late to the competitive intelligence that quietly determines whether your next launch is a triumph—or a scramble….
OpenAI’s “GPT for Life Sciences” is getting the headlines. But the real question isn’t whether the model is impressive—it’s whether it changes the economics of drug development.
Because in pharma, the bottleneck rarely looks like a lack of data. It loo…
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
Fatigue is a common side effect of Lipitor, a medication used to lower cholesterol levels and prevent heart disease. According… https://www.Drugchatter.com/chat/16688/do-you-often-feel-tired-after-taking-lipitor/
DrugChatter: Do you often feel tired after taking lipitor? Read Post »
Yervoy, also known as ipilimumab, is a medication used to treat melanoma. It has been on the market since March 2011 and… https://www.Drugchatter.com/chat/23203/any-news-on-yervoy-s-patent-expiration/
DrugChatter: Any news on yervoy s patent expiration? Read Post »
Biosimilars don’t lose on science. They lose on timing.
Most teams in biosimilars wait until the “patent expiry date” becomes a calendar event. By then, the real work—capacity planning, equipment procurement, process validation, and regulatory readines…
Drug patent protection in Europe: it sounds simple—until you look at the clock.
For years, “how long does a drug patent last?” has been treated like a straightforward question. But in Europe, the answer is less a single date on a calendar and more a mo…
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
Drug discovery timelines are getting longer—and the cost of waiting is getting unbearable.
That’s the tension at the heart of the latest push to “slash” development timelines with AI. In a world where a single delay can mean millions in additional burn…
Slash drug discovery timelines with GPT-Rosalind Read Post »
The “Patent Expiration Cliff” Is Coming—So Why Are Many Commercial Teams Still Waiting for It to Arrive?
In pharma, the calendar is destiny. But for commercial market access teams, the real inflection point isn’t the day a patent expires—it’s the weeks…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage in pharma is supposed to be a clean story: win the patent fight, launch early, capture premium pricing, and harvest the exclusivity runway before t…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits Read Post »
Read the Clock Right: Mapping Regulatory Exclusivities for True Generic Drug Entry Timing
The generic drug market is often described as a race—but it’s really a calendar. And in today’s regulatory environment, the “finish line” isn’t just patent expira…
Get new actionable insights and updates from BiotechBlog
